

ABBOTT LABORATORIES  
Form 8-K  
May 27, 2010

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

**Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **May 24, 2010**

### **Abbott Laboratories**

*(Exact Name of Registrant as Specified in its Charter)*

**Illinois**

(State or Other Jurisdiction of Incorporation)

**1-2189**

(Commission File Number)

**36-0698440**

(I.R.S. Employer Identification No.)

**100 Abbott Park Road, Abbott Park, Illinois**  
(Address of Principal Executive Offices)

**60064-6400**  
(Zip Code)

**(847) 937-6100**

(Registrant's Telephone Number, Including Area Code)

## Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



Edgar Filing: ABBOTT LABORATORIES - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Abbott Laboratories

May 27, 2010

By: /s/ Thomas C. Freyman  
Name: Thomas C. Freyman  
Title: Executive Vice President, Finance and Chief  
Financial Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Exhibit</b>
99.1	Underwriting Agreement
99.2	Pricing Agreement
99.3	Actions of the Authorized Officers (Exhibits A-1, A-2, A-3 and B to Exhibit 99.3 are filed as Exhibits 99.4, 99.5, 99.6 and 99.2, respectively, to this Form 8-K)
99.4	Form of 2015 Note
99.5	Form of 2020 Note
99.6	Form of 2040 Note
99.7	Opinion of Mayer Brown LLP
99.8	Consent of Mayer Brown LLP (included in Exhibit 99.7 hereto)